I. Overview of the Peptide Drug Industry
Peptide drugs are specific applications of peptides in the pharmaceutical sector, mainly manufactured via chemical synthesis, genetic recombination, or extraction from animals and plants. With molecular weights ranging from 500 to 10,000, they fall between small‑molecule chemical drugs and protein therapeutics, combining features of both. Peptide drugs feature quality control standards similar to small‑molecule drugs and biological activity comparable to protein drugs, delivering unique advantages in clinical use and production.

In recent years, the Chinese government has successively issued policies to support the development of the pharmaceutical sector, providing full backing for the advancement of biopharmaceuticals, including peptide drugs. The “Guidelines for Clinical Application of Novel Antitumor Drugs (2023 Edition)” states: To standardize the clinical application of novel antitumor drugs and enhance their efficacy and safety, the National Health Commission has revised and released these guidelines, offering clear recommendations on drug selection, combination therapy, and administration in clinical practice. The aim is to optimize therapeutic outcomes while minimizing adverse reactions.

II. Industrial Chain of the Peptide Drug Industry
1. Industrial Chain Structure
The upstream of the peptide drug industry mainly consists of raw material suppliers, providing amino acids, amino acid protectants, resin acids, synthesizers, packaging materials, instruments and equipment. The midstream is dominated by peptide drug manufacturers. The downstream covers sales terminals: pharmaceutical wholesalers supply medical institutions, with products ultimately sold to patients.

2. Downstream Analysis
Peptide drugs are mainly applied in oncology, digestive diseases, diabetes, cardiovascular‑cerebrovascular diseases, anti‑infection and other fields. Oncology takes the largest market share at 30.35%, followed by diabetes (13.77%) and digestive diseases (13.75%).

IV. Development Status of the Peptide Drug Industry Accelerated global population aging and rising incidence of chronic diseases, including growing patient numbers with diabetes and cardiovascularcerebrovascular conditions, drive strong demand for peptide therapeutics in chronic disease treatments such as diabetes and oncology, thanks to their high specificity and low toxic side effects, laying a foundation for market expansion. Statistics show the global peptide drug market grows yearonyear, reaching approximately USD 87.6 billion in 2024.

V. Development Trends of the Peptide Drug Industry ## 1. Improved Drug Delivery Longacting technologies greatly extend dosing intervals and enhance patient compliance. Breakthroughs in oral peptide technology have been achieved, with 8 domestic firms developing oral insulin pipelines, 3 of which have entered clinical trials. ## 2. Higher R&D Efficiency AIassisted peptide design significantly shortens R&D cycles. Several enterprises have advanced AIdesigned antidiabetic peptide drugs to Phase II clinical trials. ## 3. Accelerated New Formulation Development Formulation innovation has become a core differentiator. Novel dosage forms such as inhalants and transdermal patches are entering clinical research. This report conducts an indepth analysis of China’s peptide drug industry covering development status, market supplydemand dynamics, upstreamdownstream industrial chains and competitive landscape, helping enterprises reduce investment risks and operational costs while boosting competitiveness. Multiple data analysis technologies are adopted to forecast industry trends, enabling companies to seize market opportunities timely.

Changsha Luocheng Trading Co., Ltd. is a specialized supplier of high-purity peptides for the cosmetic, wellness, and fitness industries. Our core products include cosmetic peptides, anti-aging peptides, weight management peptides, and muscle-building peptides – serving skincare brands, supplement formulators, and health-focused companies worldwide.